CVKD יחס מהיר Cadrenal Therapeutics

Cadrenal Therapeutics (CVKD) is optimizing personnel costs and research accuracy through digital monitoring and trial data automation. This chart shows the market price corresponds to the value 3.63. The business currently lacks commercial revenue, as its capitalization depends on the results of anticoagulant tests. However, patents for Tecarfarin will provide significant pricing power in the future due to the unique protection offered to dialysis patients.

For the biotech sector company Cadrenal Therapeutics (CVKD), which is focused on advancing Tecarfarin through the FDA, the critical liquidity ratio serves as an indicator of management's ability to fund the regulatory track without emergency capital raises. This metric measures resilience against cash flow gaps by comparing cash and accounts receivable against short-term liabilities, excluding illiquid inventories to ensure the most conservative assessment of the business's solvency.